DEM BioPharma, backed by an impressive list of investors, debuted Thursday with $70 million that will assist in its efforts to treat cancer with an approach that leverages CRISPR screening and macrophage biology in immuno-oncology.
https://www.pharmalive.com/wp-content/uploads/2022/06/DEMBioPharma-logo-2022.jpg252612BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-06-23 10:12:142022-06-23 10:54:59Pfizer-backed DEM Bio launches to leverage CRISPR in immuno-oncology
